StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Venclexta (venetoclax) by Year

Venclexta (venetoclax) — International operational (constant-currency) growth YoY (%) (%)

QuarterlyAnnual

AbbVie Venclexta (venetoclax): 9.8% in FY2025, down 8.2 pts from a year earlier.

Latest, FY2025
9.8%
Period ended Dec 31, 2025
Change on a year earlier
-8.2 pts
18.0% in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below

Where the FY2025 figure comes from

“|| Venclexta | 1,306 | 1,486 | 2,792 | 5.9 | 10.2 | 8.1 | 9.8 | 7.9”

Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVenclexta (venetoclax) — International operational (constant-currency) growth YoY (%) (%)Year on yearSource
FY2025Dec 31, 20259.8%-8.2 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
FY2024Dec 31, 202418.0%-4.3 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
FY2023Dec 31, 202322.3%-2.3 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
FY2022Dec 31, 202224.6%+8.5 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
FY2021Dec 31, 202116.1%-38.3 ptsForm 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗
FY2020Dec 31, 202054.4%–Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗

Cite this data

StockData. (2026). AbbVie Venclexta (venetoclax) (%), annual FY2020–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/venclexta-intl-op-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.